Topotecan Vs. Topotecan + Etoposide Vs.Topotecan + Gemcitabine in Ovarian Cancer Therapy

• Status: Completed
• Trial end date: 2009-12-01
• Target enrollment: 0
• Participant gender: Female

Summary

Determination of total survival under Topotecan Monotherapy, Topotecan + Etoposide and Topotecan + Gemcitabine in second-line therapy in patient with recurrent ovarian cancer.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: North Eastern German Society of Gynaecological Oncology; North Eastern Germany Society of Gynaecologic Oncology
• Treatments: Etoposide; Gemcitabine; Topotecan

Criteria

Inclusion Criteria:

• Patient with recurrent ovarian cancer

• Second-line chemotherapy

• > = 18 years of age

• ECOG < = 2

Exclusion Criteria:

• ECOG > 2

• Patients with more than one chemotherapy in anamneses